Last reviewed · How we verify

LPV — Competitive Intelligence Brief

LPV (LPV) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIV protease inhibitor. Area: Infectious Disease.

phase 3 HIV protease inhibitor HIV-1 protease Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

LPV (LPV) — Bristol-Myers Squibb. LPV is a protease inhibitor that blocks HIV protease, preventing the maturation of HIV virions and reducing viral replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
LPV TARGET LPV Bristol-Myers Squibb phase 3 HIV protease inhibitor HIV-1 protease
Riv riv Pfizer marketed Protease Inhibitors HIV-1 protease
Triple therapy with ritonavir Triple therapy with ritonavir Sociedad Andaluza de Enfermedades Infecciosas marketed HIV protease inhibitor HIV-1 protease
lopinavir/ritonavir (LPV/r) lopinavir/ritonavir (LPV/r) French National Agency for Research on AIDS and Viral Hepatitis phase 3 Protease inhibitor HIV-1 protease
TMC114 TMC114 Tibotec Pharmaceuticals, Ireland phase 3 protease inhibitor HIV-1 protease
LEXIVA (GW433908) LEXIVA (GW433908) ViiV Healthcare phase 3 HIV protease inhibitor HIV-1 protease
abacavir/lamivudine + darunavir/ritonavir abacavir/lamivudine + darunavir/ritonavir University of Modena and Reggio Emilia phase 3 NRTI + PI HIV-1 reverse transcriptase, HIV-1 protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIV protease inhibitor class)

  1. Bristol-Myers Squibb · 5 drugs in this class
  2. ViiV Healthcare · 3 drugs in this class
  3. GlaxoSmithKline · 2 drugs in this class
  4. Drugs for Neglected Diseases · 2 drugs in this class
  5. Germans Trias i Pujol Hospital · 2 drugs in this class
  6. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
  7. DualityBio Inc. · 1 drug in this class
  8. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
  9. Far East Bio-Tec Co., Ltd · 1 drug in this class
  10. Community Research Initiative of New England · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LPV — Competitive Intelligence Brief. https://druglandscape.com/ci/lpv. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: